Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
DiabetesontheNet Logo


Share this article
Share on facebook
Share on twitter
Share on email
Share on print

HbA 1c: Chasing numbers or considering context?

Glycated haemoglobin (HbA1c) reflects the average blood glucose level in the three months preceding the test. Changes in consecutive HbA1c tests indicate deteriorating, or improved, glycaemic control. HbA1c is considered to be the “gold standard” measure of blood glucose control and is often used as the basis for prescribing choices and other care decisions. A number of factors can affect the accuracy of the HbA1c result, for example, the life span of red blood cells, assay methods and clinicians’ awareness of possible interfering factors. The aim of this article is to outline how HbA1c is used as a diagnostic test, how it is used to monitor glycaemic control and how it can guide management decisions. It is also important to emphasise the importance of considering HbA1c in the context of the individual rather than as an isolated number.

Glycated haemoglobin (HbA1c) is an important guide to glycaemic control and influences treatment decisions. Several epidemiological studies, including the DCCT (Diabetes Control and Complications Trial; 1993) and the UKPDS (United Kingdom Prospective Diabetes Study; Turner et al, 1998) demonstrated that elevated HbA1c is a strong predictor of diabetes-related morbidity. Two consecutive HbA1c levels greater than 48 mmol/mol (6.5%) is associated with a linear increase in the incidence of diabetes complications, especially if the HbA1c values continue to increase (DCCT, 1993; Turner et al, 1998). Consequently, HbA1c is now an accepted measure of long-term glycaemia, as well as a clinically relevant measure of glycaemic control. 

Although, there is an increasing body of evidence to suggest HbA1c alone does not always accurately reflect the individual’s metabolic status (Weber and Schnell, 2009). Recent research suggests glucose variability (peaks and nadirs lasting minutes to hours during the day) is a risk factor for microalbuminuria (Hsu et al, 2012), adverse cardiovascular outcomes (Picconi et al, 2012) and all-cause mortality in type 2 diabetes (Ma et al, 2011).

Glycaemia and diabetes management
HbA1c was measured chromatographically in the DCCT and UKPDS. Chromographic methods detect several haemoglobin variants and non-HbA1c glycohaemoglobins and tend to overestimate HbA1c compared to modern assay methods (Larese, 2012). A considerable international effort has been undertaken in recent years to standardise existing HbA1c assays in current use and to standardise how glycated haemoglobin and estimated average blood glucose are reported (National Glycohemoglobin Standardisation Program,

HbA1c in people without diabetes usually ranges between 20 and 41 mmol/mol (4–5.9%;, 2013). HbA1c consistently >53 mmol/mol (7%) in people with diabetes represents inadequate glycaemic control and is associated with increased risk of long-term diabetes complications (Ray et al, 2009). The American Diabetes Association (ADA, 2011) and the World Health Organisation (WHO, 2011) recommend aiming for an HbA1c value <48 mmol/mol (6.5%).

NICE (2009) guidelines for type 2 diabetes recommend aiming for HbA1c levels <48 mmol/mol (6.5%) for people taking one blood glucose-lowering medicine (GLM) and <58 mmol/mol (7.5%) for those taking two or more GLMs. However, NICE acknowledged these levels may not be appropriate for all people with type 2 diabetes. Likewise, the Australian Diabetes Society (ADS, 2009) suggested a general HbA1c target of <53 mmol/mol (7%), but indicated some people should aim for <42 mmol/mol (6%) and some <64 mmol/mol (8%), depending on individual circumstances.

Significantly, HbA1c <53 mmol/mol (7%) is associated with more frequent hypoglycaemia, which puts some people with diabetes, particularly older people, at increased risk of adverse events, including cognitive impairment, impaired decision-making, falls and myocardial infarction (The ACCORD Study Group, 2011). Thus, there is growing recognition that HbA1c levels <53 mmol/mol (7%) may not be appropriate for everybody with diabetes and that management goals need to be individualised, especially in children and older people (ADS, 2009; NICE, 2009; Gale, 2010; Scottish Intercollegiate Guideline Network, 2010). 

ADA (2011) have indicated that  HbA1c values of 37–48 mmol/mol (5.7–6.4%) represent pre-diabetes, which is part of a continuum of diabetes risk and a marker of cardiovascular disease, and identifying pre-diabetes enables early treatment to be implemented to reduce the risk. Some authorities suggest repeating the test in asymptomatic people (d’Emden et al, 2012), which could mean diabetes is diagnosed earlier and treatment can be initiated sooner.  Likewise, the WHO (2011) cautioned that an HbA1c <48 mmol/mol (6.5%) does not exclude diabetes. In addition, it is important to consider factors that cause false high or low HbA1c when interpreting results before making a definitive diagnosis.

HbA1c as a diagnostic tool
The WHO (2011), International Diabetes Federation (IDF; 2013) and the ADA (2011) recommend that HbA1c is used as a diagnostic test for diabetes and cited values of HbA1c 48 mmol/mol (6.5%) as the diagnostic cut-off point.  HbA1c overcomes some of the methodological, procedural and practical problems associated with using blood glucose to make the diagnosis. These include the significant day-to-day variations in blood glucose levels, the fall in blood glucose concentration in blood samples, even when they are collected in fluoride-oxalate tubes, and inter-laboratory variations (d’Emden et al, 2012). 

In Australia, d’Emden et al (2012) have stated that HbA1c has an important place in diagnosis when using the recommended diagnostic cut-off point, but suggested the test should be repeated in asymptomatic people with a diagnostic HbA1c result to confirm the diagnosis. They further stated that HbA1c should not be used as a general diabetes screening test and that initial screening should still be based on the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) score (Australian Government Department of Health and Ageing, 2008).  The AUSDRISK is widely used in Australia to screen for diabetes; other countries have similar screening tools, such as the UK Diabetes Risk Score (Diabetes UK, 2013). In addition, d’Emden et al recommend that health professionals consider other factors that can affect the HbA1c level when interpreting the result and making management decisions; see Box 1 and Table 1.

HbA1c is less reliable as a diagnostic tool in certain groups people, for example, those with cystic fibrosis-related diabetes (Dyce and Wallymahmed, 2012); people on long-term corticosteroid medicines (Tidy, 2012); those with long-standing iron deficiency anaemia (Stranks and Doogue, 2012) and people with renal disease on haemodialysis (Vos et al, 2011). In addition, point-of-care HbA1c test methods are useful to monitor glycaemic control but may not be accurate enough to diagnose diabetes (International Expert Committee, 2009).

Factors that affect HbA1c
A number of factors can affect HbA1c, especially conditions that affect red blood cell survival and non-enzymatic glycosylation of haemoglobin (Herman, 2009; d’Emden et al, 2012). Herman (2009) suggested only approximately one third of the variance in HbA1c is due to glycaemia. Other factors that affect HbA1c include genetics, female gender, sex hormones, visceral fat distribution (Cohen et al, 2006) and the HbA1c assay method. For example, immunoassay methods yield lower results than high performance liquid chromatography (HPLC; Schweitzer et al, 2012). 

Formation of glycated haemoglobin
Glycation is a non-enzymatic, time-dependent chemical process during which glucose binds to the amino proteins in various tissues in the body (Little and Roberts, 2009). Glucose attaches to haemoglobin in the blood and several processes occur to form HbA1c. Several HbA peaks can be observed on chromographic assays: HbA1a, HbA1b and HbA1c. HbA comprises 96–98% of the total haemoglobin and HbA1c is the dominant component that correlates with the mean serum glucose. Thus, HbA1c specifically refers to glycohaemoglobin where glucose binds to the terminal valine of the beta-haemoglobin chain to form an adimine link, which undergoes an Amadori reaction and forms a stable ketoamine link.  

Glycosylated and non-glycosylated hexapeptides are separated using HPLC and quantified. HbA1c is reported as the ratio of its concentration to total HbA (Jeppsson et al, 2002) and represents the average blood glucose over the preceding 2–3 months (Nitin, 2010). Fasting plasma glucose (FPG) and post-prandial glucose (PPG) have the same effect on HbA1c <53–64 mmol/mol (7.3–8.4%). However, FPG has a greater effect when HbA1c is >63 mmol/mol (8.5%); the higher the HbA1c, the more FPG contributes to total blood glucose.

HbA1c assays
Several assay methods are used to measure HbA1c including iron exchange, HPLC, chemiluminiscent immunoassays, boronate affinity and enzymatic methods (Herman 2009; Nitin 2010). The US-based National Glycohemoglobin Standardisation Program was established in 1996 to standardise the various methods to the DCCT trial equivalent methods (Herman, 2009). Each year the College of American Pathologists compares within and between HbA1c values and publishes the findings. These initiatives have improved comparability among the various methods. However, as indicated, a number of factors, independent of the method, can affect the results (Box 1 and Table 1) and need to be considered when interpreting the individual’s HbA1c results.

Considering the individual
The preceding information raises several important points that support the need to interpret the HbA1c results in the context of the individual, including whether the HbA1c value is diagnostic of diabetes, warrants a management change, or represents a complication risk.  HbA1c does not always reflect the individual’s blood glucose self-monitoring pattern for a number of reasons, including inaccurate testing technique. HbA1c is unreliable when erythrocyte abnormalities are present (d’Emden et al, 2012) and in the presence of haemoglobinopathies (Weber and Schnell, 2009) and anaemia. Weber and Schnell (2009) reported that seven out of 29 people (24%) with lower than expected HbA1c based on their home blood glucose test results had a haemoglobinopathy detected on electrophoreses.

Haemoglobinopathies are inherited abnormalities of haemoglobin and are often asymptomatic. Haemoglobinopathies are one of the most common factors affecting HbA1c levels worldwide, depending on the assay used to measure HbA1c. Most HbA1c assays assume the individual has a normal erythrocyte lifespan and that the assay method is specific for non-enzymatic adduction of glucose to haemoglobin, which may not be the case if the individual has a haemoglobinopathy. There are several haemoglobinopathies, including thalassaemia and many other Hb variants (see Box 1). Haemoglobinopathies commonly occur in people from Africa, the Mediterranean and south-east Asia and are uncommon in Caucasian people. Research has shown that the difference in HbA1c between Black people and Caucasian people becomes greater as the blood glucose increases, and is higher in Black people than Causcasian people at the same blood glucose level (Ziemer et al, 2010).  

Many countries have multicultural populations and intermarriage is becoming increasingly common; therefore, health professionals need to consider haemoglobinopathies and other factors that affect HbA1c when interpreting results.  It is possible to screen for haemoglobinopathies but few countries have haemoglobinopathy screening programmes in place. The British Society for Haematology developed guidelines for antenatal and newborn haemoglobinopathy screening, which recommend selectively screening high-risk women and that universal screening might be warranted in areas with a high proportion of at-risk individuals (Ryan et al, 2010). It is not clear whether these recommendations are in routine use.  Screening for haemoglobinipathies does not appear to be established in other countries.

HbA1c can be spuriously elevated or lowered by a number of interfering factors besides haemoglobinopathies. For example, factors that reduce the lifespan of red blood cells lead to low HbA1c. Factors that lead to increased HbA1c include infections and medicines such as corticosteroids and antipsychotics. Table 1 depicts some factors known to reduce or increase HbA1c.

Person-centred care is an important philosophy underlying modern diabetes education and management, and this should be applied to interpreting HbA1c. HbA1c is part of an individual’s clinical picture and needs to be considered in context because it does not portray the whole picture. 

Factors that affect the HbA1c need to be identified and managed. In addition, it is important to:

  • Involve the individual and any family  members or carers in decisions about  investigative procedures and care.
  • Listen to the individual with diabetes and ask appropriate questions to identify factors that could influence education and management decisions.
  • Understand haemoglobinopathies are rare in Caucasian people, but do occur, especially in multicultural societies. Consider whether individuals from at-risk groups should be screened for a haemoglobinopathy.
  • Realise very few countries have effective screening programs to detect haemoglobinopathies before or at birth. Thus, the true prevalence may be unknown in specific countries and populations.
  • Consider common and uncommon factors that increase or lower HbA1c when deciding an individual’s diabetes management regimen.
  • Consider using fructosamine to monitor glycaemic status as an alternative to HbA1c in individuals where HbA1c is unreliable.  Fructosamine assays have been available since the 1980s but are not widely used in most countries. Fructosamine is formed in a non-enzymatic process where protein, especially serum albumin, is glycosylated. Fructosamine reflects the average blood glucose over the preceding 14–21 days; therefore, it can be useful to monitor short-term management changes, especially during pregnancy. There is no standard reference range for fructosamine; generally, the higher the fructosamine level, the higher the blood glucose. Like other targets, the fructosamine target should be individualised in collaboration with the individual. Any condition that affects serum albumin, such as nephritic syndrome or malnutrition, can interfere with the fructosamine result. Thus, the individual’s health status and context must be considered when interpreting fructosamine results.
  • Know the factors that lower HbA1c could impact on its utility as a diagnostic tool and that diagnoses could be missed or delayed and place the individual at risk of diabetes complications.
  • Include prompts on pathology reports to alert health professionals to the need to check the individual’s blood glucose pattern and consider the possibility of red blood cell abnormalities and other HbA1c-related interfering factors if the HbA1c is repeatedly 42 mmol/mol (6%). Alerts are often used in this way to signal high HbA1c. However, clinicians might only refer to the results and not consider alert messages in busy clinical settings.

Managing diabetes is complicated for both health professionals and people with diabetes. It is important to individualise care and respect the person’s accumulated life and diabetes expertise.  A number of factors beside blood glucose affect HbA1c levels and need to be considered when making therapeutic and diagnostic decisions. Clearly, HbA1c (and fructosamine, if it is used) is only part of the individual’s diabetes story and should be considered with blood glucose self-monitoring tests and other important information.

ACCORD Study Group (2011) Long term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364: 818–28
American Diabetes Association (2011) Standards of Medical Care in Diabetes – 2011. Diabetes Care 33: S11–S61
Australian Diabetes Society (2009) Position Statement: Individualization of HbA1c Targets for Adults with Diabetes Mellitus. ADS, Sydney, Australia. Available at: (accessed 10.12.13)
Australian Government, Department of Health and Ageing (2008). The Australian Type 2 Diabetes Risk Assessment Tool. Australian Government, Canberra, Australia. Available at: (accessed 11.12.13)
Cohen R, Snieder H, Lindsell C et al (2006) Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care 29: 1739–43
d’Emden MC, Shaw JE, Colman PG et al (2012) The role of HbA1c in the diagnosis of diabetes mellitus in Australia. Med J Aust 197: 220–1 (2013) Guide to HbA1c. Available at: (accessed 02.01.14)
Diabetes Control and Complications Trial Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–86
Diabetes UK (2013) Diabetes risk score assessment tool. Diabetes UK, London. Available at: (accessed 02.01.14)
Dyce P, Wallymahmed M (2012) Long term complications of cystic fibrosis-related diabetes. Journal of Diabetes Nursing 16: 240–6
Gale E (2010) Diabetes in the UK: time for a reality check. Diabet Med 27: 973–6
Herman W (2009) Do race and ethnicity impact on hemogobin A1c independent of glycaemia? J Diabetes Sci Technol 3: 656–60
Hsu C, Chang H, Huang M et al (2012) HbA1c variability is associated with microalbuminuria development in type 2 diabetes: a 7-year prospective cohort study. Diabetologia 55: 3163–72
International Diabetes Federation (2013) IDF Atlas. Sixth edition. IDF, Brussels. Available at: (accessed 11.12.13).
International Expert Committee (2009) Report on the role of the HbA1c assay in the diagnosis of diabetes. Diabetes Care 32: 1327–34
Jeppsson J, Kobold U, Barr J (2002) Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 40: 78–89
Larese J (2012) When is haemoglobin A1c inaccurate in assessing glycaemic control? Clinical Correlations. Available at: (accessed 11.12.13)
Little R, Roberts W (2009) A review of variant haemoglobins interfering with hemoglobin A1c measurement. J Diabetes Sci Technol 3: 446–51
Ma W, Li HY, Pei D et al (2011) Variability in hemoglobin A1c predicts all-cause mortality in patients with type 2 diabetes. J Diabetes Complications 26: 296–300
NICE (2009) Type 2 Diabetes – Newer Agents. CG87. NICE, London. Available at: (accessed 11.12.13)
Nitin S (2010) HbA1c and factors other than diabetes mellitis affecting it. Singapore Med J 51:616–22
Picconi F, Flaviani D, Malandrucco I et al (2012) Impact of glycaemic variability on cardiovascular outcomes beyond glycated hemoglobin. Evidence and clinical perspectives. Nutr Metab Cardiovasc Dis 22:691–6
Ray KK, Seshasai S, Wijiesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373: 1765–72
Ryan K, Bain BJ, Worthington D et al (2010) Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol 149: 35–49
Schweitzer M, Cavan D, Ziegler R et al (2012) Is HbA1c a reliable measure for assessing glycaemic control. Presented at: 48th European Association for the Study of Diabetes meeting (poster 982), Berlin, Germany, 1–5 October
Scottish Intercollegiate Guideline Network (2010) Management of diabetes: A national clinical guideline. SIGN, Edinburgh
Stranks S, Doogue M (2012) Using HbA1c to test for undiagnosed diabetes. Diabetes Manag 39: 10–11
Tidy C (2012) Glycated haemoglobin (HbA1c). Available at: (accessed 02.01.14)
Turner R, Holman R, Cull C (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–53
Vos F, Schollum J, Walker R (2011) Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease. NDT Plus 4: 368–75
Weber C, Schnell O (2009) The assessment for glycaemic variability and its impact on diabetes-related complications: an overview. Diabetes Technol Ther 11: 623–33
World Health Organisation (2011) Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of WHO consultation. WHO, Geneva. Available at: (accessed 11.12.13)
Ziemer D, Kolm P, Weintraub W et al (2010) Glucose-independent black-white differences in hemoglobin A1c levels: a cross-sectional analysis of two studies. Ann Intern Med 152: 770–7

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.